RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Gilead Sciences (GILD) but lowered the price target from $78 to $76.
February 07, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained its 'Sector Perform' rating on Gilead Sciences but reduced the price target from $78 to $76.
The reduction in price target by RBC Capital, despite maintaining a 'Sector Perform' rating, could lead to a negative perception among investors, potentially causing a short-term decrease in GILD's stock price. The adjustment in price target reflects a slightly less optimistic outlook on the company's valuation or future earnings potential.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100